News Cybin expands psychedelic facilitator training program EMBARK The program is meant to offer and expand skillful and ethical lessons in the field of psychedelic therapeutics Natalia Buendia CalvilloJuly 12, 2023
Psychedelics PharmAla Biotech signs agreement to sell clinical-grade MDMA in Australia Companies are running more MDMA and psilocybin trials after the Australian drug regulation changes Natalia Buendia CalvilloFebruary 14, 2023
Psychedelics UBC graduates launch promising psychedelics startup in Nevada Married couple now run state-of-the-art laboratory in Las Vegas dedicated to advancing new therapies Rowan DunneJuly 8, 2022
Psychedelics Nirvana Life acquires exclusive license for novel psychedelic delivery system Canadian life sciences outfit continues to push the envelope in the clinical psychedelic sector Rowan DunneJuly 6, 2022
Alternative Energy Cybin receives FDA approval for new in-human clinical trial Patient enlistment for new study to treat Major Depressive Disorder set to begin promptly Rowan DunneJune 28, 2022
Coming soon PAREA: A new psychedelic-focused alliance of prominent companies with common goals Multi-organization psychedelic partnership set to launch on June 23 Rowan DunneJune 16, 2022
Business Entheon Biomedical hands off DMT clinical study to Cybin Dimethyltryptamine continues to demonstrate tremendous therapeutic potential Rowan DunneJune 14, 2022
Culture Numinus announces Music as Medicine event series Series of concerts across the U.S. and Canada will explore music’s role in psychedelic-assisted therapy Ryan GarnerMay 3, 2022
Business Numinus ups revenue 61% thanks to psychedelic-focused therapy programs Expenses were down 71% but the firm still reported a $5.4-million loss Natalia Buendia CalvilloJanuary 21, 2022
Industry update MagicMed attracts investors to advance library of psychedelic derivatives After raising $8.1M, the Calgary company filed 12 patents and launched a candidate selection program for novel psychedelic mental health treatments Jared GnamDecember 23, 2020